MULTIMODALITY AND MULTIPARAMETRIC IMAGING
IN ADVANCING HEALTHCARE
TOWARDS PERSONALIZED MEDICINE ______________________________________________________________________
Following the previously conducted symposia on dedicated medical imaging instrumentation we are presently organizing the 5th workshop of this exclusive series to be held in the East of the beautiful island of Sardinia.
The purpose of this meeting is to discuss the role of the multimodality and multi-parametric imaging modalities on the vision of individualized/personalized medicine.
Based on the breakthroughs in genomic, proteomic and metabolic profiling Precision Medicine has emerged as a novel health-care paradigm. Precision Medicine is an approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle. It involves integrating information from multiple sources to achieve a precise diagnosis, personalized target treatment, and adequate response assessment.
The “-omics” analysis as well as histopathology are important input parameters for a precise diagnosis, however, as they rely on small biopsy samples or body fluids, they do usually not map the entire profile of the disease. Tumors typically have a spatially and temporally varying molecular and genetic profile; the same applies to neurodegenerative, cardiovascular or autoimmune diseases. Therefore, “liquid diagnostic parameters” can provide only a snapshot of the entire disease while Multiparametric Imaging can holistically map molecular, functional and habitant varieties of the same or multiple diseases.
Thus, Multiparametric Imaging and Imaging-Guided Interventions, which provide multiparametric information and enable focused, minimally invasive treatments, are key elements of complex Precision Diagnosis and Personalized Medicine. Different diagnostic approaches utilizing bioinformatics, machine learning, and systems biology will be used to mine the essential information and fuse the precise but spatially and temporally restricted disease characterization of “-omics” and histopathology with the holistic data of Multiparametric Imaging. The emerging fields of Radiomics and Radiogenomics are linking genotypic information to phenotypic disease manifestations from imaging. Because of the growing volume and complexity of imaging data and its necessary linkage to metadata, decision-support algorithms will be required to help physicians applying the most essential patient data for optimal management.
Based on the above emerging realities the MEDAMI Forum series of events is trying to define the role of and needs for Multiparametric Imaging in the development of healthcare towards Personalized/Precision Medicine and to determine the impact of those developments on collaboration- and business models in the future.
What are the key questions the MEDAMI 2017 will address?
Personalized Medicine – what will be the impact of what? on current medical imaging and image guided interventions? Is there a need for organ specific (precision) medical imaging?
Which medical areas have the the strongest impact/needs?
Are there new imaging technologies and methods for precision imaging?
In which areas are new biomarkers and imaging agents needed? What shall be the role of such new tracers and imaging agents in personalized medical imaging?
What funding mechanisms can be employed for the development of imagers and imaging agents that finally lead to widespread clinical application? What are the roles of funding agencies and industry?
How does Personalized Medicine impact the business models of stakeholders (industries, clinics, health care providers)?
The program of the MEDAMI 2017 is being developed . A number of Key Opinion Leaders (KOL’s) from Biology, Medicine and Technology fields have already been contacted to give lectures.
The program of the forum primarily will consist of invited talks by key opinion leaders and experts from around the world. However, a limited number of abstracts for oral or poster presentations will be accepted. If you have to report on a topic that you think fits into the scope of the program we will be happy to receive your abstract.
Preliminary list of key speakers who accepted to come and talk:
- Prof. Roderic Pettigrew, director of the National Institute of Biomedical Imaging and Bioengineering (NIBIB)- USA
- Prof. David Townsend, National University of Singapore, inventor of PET/CT
- Prof. Craig Levin, Stanford Molecular Imaging Instrumentation Laboratory (MIIL) – USA
- Prof. Bernd Pichler, University of Tubingen (Germany)
The meeting format fosters a close interaction between different stakeholders from academia, medical institutions and organizations, regulatory agencies and industry.
Nicolas Petrick (Center for Devices and Radiological Health (CDRH), Food and Drug Administration (FDA)) - FDA perspective on the role of FDA in the emerging field of precision medicine medical imaging35m
Abstract
9:35 AM
Bernd Stowasser (Sanofi-Aventis, on behalf of the European Federation of Pharmaceutical Industries and Associations (EFPIA)) - Academic-Industry partnership: Can the IMI PPP model be extended/exported to medical imaging industry?35m
Session 1.2: Research concepts/activities (Moderator: York Haemisch)
10:40 AM
Piotr Maniawski (Philips Healthcare, on behalf of the Association of Imaging Producers and Equipment Suppliers (AIPES)) - The AIPES organization and its role in supporting medical imaging development25m
Abstract
11:05 AM
Marco Paganoni (Univ. of Milano) - ERAMIT25m
Abstract
11:30 AM
Maurizio Conti (Siemens Healthineers, Knoxville) - Challenges and trends in molecular imaging, an industry research viewpoint. The role of radiotracers in modern diagnosis and expensive/advanced therapies30m
12:00 PM
→
2:30 PM
Lunch break
2h 30m
12:00 PM
→
2:30 PM
Poster Session
2:30 PM
→
4:15 PM
Session 1.3: Diagnostic Imaging, theranostics and the -omics (Moderators: Bernd Pichler, Jonathan Disselhorst)
2:30 PM
David Townsend (National University of Singapore) - PET/CT, PET/MR and Precision Medicine: some alternative facts35m
3:05 PM
Bernd Pichler (Dept. of Pre-clinical imaging and Radiopharmacy University of Tuebingen) - Combining multiparametric imaging data with –omics information for precision medicine35m
3:40 PM
Constantin Lapa (Nuclear Medicine, University of Wurzburg) - Theranostics and multimodality imaging35m
Abstract
4:15 PM
→
4:45 PM
Coffee break
30m
4:45 PM
→
6:25 PM
Session 1.3 (cont)
4:45 PM
Jonathan A. Disselhorst (University Tuebingen) - Imaging Tumor Heterogeneity35m
Abstract
5:20 PM
P. Pevsner - How cost-effectiveness of a diagnostic medical imaging procedure is determined30m
5:50 PM
Roderic Pettigrew (Director of the National Institute of Biomedical Imaging and Bioengineering (NIBIB)) - Multimodality/Multiparametric Imaging and Precision Medicine35m
6:25 PM
→
7:30 PM
ROUND TABLE - The relation of academia and industry in the development of medical and molecular imaging technologies. Chair: Paul. Lecoq, CERN - Representatives of funding institutions, industries, MDs, physicists/technologists Outcome: proposals for improvement of academia-industry relation
Session 2.1: Neurodegenerative diseases and brain disorders
8:30 AM
Charles R.G. Guttman (Center for Neurological Imaging, Harvard Medical School) - Neurodegenerative diseases - an overview30m
Abstract
9:00 AM
Valentina Garibotto (Univ.of Geneva) - Multimodal/multiparamenter imaging – main modalities and applications: link to biomarkers and personalized medicine30m
Abstract
Slides
9:30 AM
Martin Walter (University of Tuebingen, Germany) -Multimodal imaging in psychiatry30m
10:00 AM
Vesna Sossi (University of British Columbia) - PET/MRI imaging in neurodegeneration: novel metrics for early disease detection and effect of therapy assessment30m
Abstract
10:30 AM
→
11:00 AM
Lunch break
30m
11:00 AM
→
1:00 PM
Session 2.2: Brain biomarkers and brain imaging initiatives
11:00 AM
Christer Halldin (Karolinska Institutet, Stockholm) - PET Radioligands for Neuroscience and Drug Development30m
Abstract
Slides
11:30 AM
Ilan Rabiner (Chief Medical Officer, Head of Imaging Applications, Imanova Ltd., UK) - Building the Three Pillars- Imaging in early phase drug development30m
Abstract
12:00 PM
Paul M. Matthews (Head of Brain Imaging Sciences, Imperial College, London) - Challenges and opportunities for brain imaging with large population datasets30m
Abstract
12:30 PM
Simone Sarasso (Dept. of Biomedical Sciences, University of Milano) - Major brain initiatives30m
1:00 PM
→
4:00 PM
Lunch break
3h
1:00 PM
→
4:00 PM
Poster Session
4:00 PM
→
4:50 PM
Session 2.3: Brain imaging - new technologies
4:00 PM
Stan Majewski (University of Virginia) - Dedicated PET brain imaging devices25m
Abstract
4:25 PM
Bernd Pichler (Director, Dept. of Pre-clinical imaging and Radiopharmacy, University of Tuebingen) - Developments in MRI, MEG and EEG25m
4:50 PM
→
5:20 PM
Coffee break
30m
5:20 PM
→
6:35 PM
Session 2.3: Brain imaging - new technologies
5:20 PM
Jose Maria Benlloch (Institute of Molecular Imaging, University of Valencia) - Mindview: multimodal imaging of neurological disorders25m
5:45 PM
Alberto del Guerra (Department of Physics, University of Pisa) - A trimodality (EEG/MR/PET) scanner for brain imaging25m
Abstract
Slides
6:10 PM
Contributions25m
6:35 PM
→
7:35 PM
ROUND TABLE - Molecular imaging and -omics: competition or complementarity for Precision medicine? Chair: Vesna Sossi, UBC, Vancouver Representatives of funding institutions, industries, MDs, physicists/technologists
Session 3.1: New Technologies for Molecular Imaging
8:30 AM
Paul Lecoq (CERN, Geneva) - The 10 ps TOF-PET challenge25m
8:55 AM
Dennis Schaart (Department of Rad. Science & Technology, TU Delft) - Fundamentals of Ultrafast Timing25m
Abstract
9:20 AM
Terry Jones (UCL, London) - The Explorer project: a new paradigm in nuclear medicine?35m
Abstract
9:55 AM
Piotr Maniawski (Philips Healthcare, Cleveland) - Digital Photon Counting PET: technology powering precision molecular imaging30m
Abstract
10:25 AM
→
10:55 AM
Coffee break
30m
10:55 AM
→
12:40 PM
Session 3.1 (cont)
10:55 AM
Bipin Singh (RMD Watertown, Ma) - Photonic Crystal Enhances Scintillation Light Extraction: Can It Improve Timing Resolution?20m
Abstract
Slides
11:15 AM
Claudio Piemonte (FBK Trento) - New high performance SiPM arrays with TSV technology for TOF and other applications25m
11:40 AM
Stefaan Tavernier (PETsys Electronics SA, Lisbon) - TOFPET II: The next generation ASIC for TOF-applications25m
Abstract
12:05 PM
Gabriela Llosa (Instituto de Fisica Corpuscular, University of Valencia) - From MACACO to MACACO II: a Compton telescope for hadron therapy treatment monitoring20m
Abstract
Slides
12:25 PM
Ilaria Mattei (INFN Milano) - Characterisation of the secondary fast and ultrafast neutrons emitted in Particle Therapy with the MONDO experiment15m
Abstract
12:40 PM
→
3:40 PM
Lunch break
3h
12:40 PM
→
3:40 PM
Poster Session
3:40 PM
→
4:30 PM
Session 3.2: Molecular Imaging in the diagnosis, treatment and follow up of breast cancer
3:40 PM
Orazio Schillaci (TOV Policlinico Tor Vergata, Roma) - The role of Nuclear Medicine in breast cancer management25m
Abstract
4:05 PM
Michael O’ Connor (Mayo Clinic Rochester) - Breast cancer screening with single gamma and positron emitters25m
4:30 PM
→
5:30 PM
Coffee break
1h
4:30 PM
→
5:30 PM
Poster Session
5:30 PM
→
6:45 PM
Session 3.3: Technologies for breast imaging/diagnosis
5:30 PM
Evaristo Cisbani (ISS and INFN, Roma) - A novel SPECT-Thomosynthesis detector for the diagnosis and follow up of breast cancer25m
5:55 PM
Michel Herranz (Univ. of Santiago de Compostela) - Dedicated breast PET (dbPET) in diagnosis and follow up of breast cancer - comparison, synergies and divergences with MRI25m
6:20 PM
Volkmar Schulz (University of Aachen, DE) - PET-MR dedicated detector for breast cancer diagnosis and follow – up25m
Abstract
6:45 PM
→
7:45 PM
ROUND TABLE - Multimodality multiparametric imaging in cancer management: How can it be improved? (Chair: David Townsend, Singapore)
Session 4.1: Molecular Imaging in the management of prostate cancer
8:00 AM
H. Van der Pohel (Amsterdam, Ne) - Multimodality imaging in surgery25m
Abstract
8:25 AM
Tobias Maurer (Klinikum rechts der Isar, TU Munich) - Shifting gears in Imaging - how PSMA-PET is about to change prostate cancer diagnosis25m
Abstract
8:50 AM
Valeria Panebianco (Università degli Studi di Roma La Sapienza) - The role of multiparametric MR in the diagnosis and follow up of prostate cancer25m
9:15 AM
Paul Lecoq (CERN, Geneva) - ENDO-TOF-PET-US in the diagnosis and follow up of prostate cancer25m
9:40 AM
→
10:10 AM
Coffee break
30m
10:10 AM
→
10:55 AM
Session 4.1: Molecular Imaging in the management of prostate cancer
10:10 AM
Franco Garibaldi (AIB, Roma) - TOF-PET-MR in the diagnosis and follow up of the prostate cancer25m
10:35 AM
Nicoletta Protti (INFN Pavia) - In vivo 10B imaging and dose rate measurement for Boron Neutron Capture Therapy (BNCT) using Single Photon Emission Computed Tomography (BNCT-SPECT)20m
Session 5.1: Molecular Imaging in surgical interventions
8:00 AM
Fijs van Leuven (LUMC, Leiden) - Multimodality imaging techniques in surgery25m
Slides
8:25 AM
Tobias Maurer (Klinikum rechts der Isar, TU Munich) - PSMA radioguided surgery – a novel technique for intraoperative detection of prostate cancer metastases20m
8:45 AM
Elena Solfaroli (Università degli Studi di Roma La Sapienza) - Radioguided surgery with beta-radiation: test on ex-vivo specimen20m
Abstract
Slides
9:05 AM
Image guided robotic surgery in lung cancer. (... to be decided)20m
9:25 AM
→
9:55 AM
Coffee break
30m
9:55 AM
→
11:05 AM
Session 5.2: Molecular Imaging in Hadron Therapy Monitoring
9:55 AM
P. Cerello (INFN Torino) - Imaging in hadron therapy25m
Abstract
10:20 AM
F. Pennazio, INFN Torino) - The INSIDE project: hadron therapy monitoring with in-beam PET25m
Abstract
Slides
10:45 AM
Ilaria Mattei (INFN Milano) - Study of the radiation produced by therapeutic He, C and O ion beams impinging on a PMMA target for beam range monitoring purpose in Particle Therapy20m